journal article·2025-05Open access

Fast Prototyping and Ex Vivo Evaluation of Dissolvable Millineedle Patches Made by Solvent Casting from CO2 Laser Ablated Elastomer Molds

Matteo Tollemeto, Lasse Højlund Eklund Thamdrup, Veni Mahalingam, Gavrielle R. Untracht, Tania Patiño Padial, Peter Eskil Andersen, Jan van Hest, Anja Boisen

Advanced Materials Interfaces· Volume 12· Issue 10

Abstract

Abstract In this study, a highly feasible fabrication approach is explored to make flexible elastomer molds for producing transdermal patches comprising an array of millimeter‐long dissolvable polymer needles. The millineedles (MilN), produced in both polyvinylpyrrolidone and carboxymethyl cellulose, are targeting efficient transdermal drug delivery. Employing a fast, inexpensive, and reproducible CO2 laser ablation process, polydimethylsiloxane molds are successfully created measuring 10 × 10 mm2, with arrays of conical cavities reaching depths of 1288.17 ± 128.93 µm. While this versatile fabrication technique is previously demonstrated for microneedles, it lacked a comprehensive performance evaluation of the produced needles. The study fills this gap by providing significant experimental data on the in vitro and ex vivo performance of the MilN patches. The applicability of the method is demonstrated by systematically casting and testing patches comprising various hydrophilic polymers and compounds. Mechanical testing underscored the resilience of MilN arrays, enduring compression forces up to 36 N for 30 s. Skin penetration efficiency, assessed in Parafilm M and porcine skin, revealed an insertion depth of ≈560 µm for polyvinylpyrrolidone MilN.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Bee Products Chemical Analysis · Botulinum Toxin and Related Neurological Disorders

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

The Danish National Research Foundation and Villum Foundation's Center IDUN Department of Health Technology Technical University of Denmark Kgs. Lyngby 2800 Denmark

OASIS Department of Health Technology Technical University of Denmark Kgs. Lyngby 2800 Denmark

Department of Biomedical Engineering Institute for Complex Molecular Systems Eindhoven University of Technology Eindhoven 5612 AZ The Netherlands

Funding

Horizon 2020 Framework Programme · Novo Nordisk Fonden · Villum Fonden · Danmarks Grundforskningsfond

References (41)

Show source-provided references
1. 10.1038/nrd.2018.18310.1038/nrd.2018.183 ↗
2. 10.1016/S1461-5347(00)00295-910.1016/S1461-5347(00)00295-9 ↗
3. 10.1038/nbt.150410.1038/nbt.1504 ↗
4. 10.1186/s40824-021-00226-610.1186/s40824-021-00226-6 ↗
5. 10.3390/pharmaceutics703009010.3390/pharmaceutics7030090 ↗
6. 10.1038/nbt0204-16510.1038/nbt0204-165 ↗
7. 10.3109/1071754100366779810.3109/10717541003667798 ↗
8. 10.1039/D3BM00262D10.1039/D3BM00262D ↗
9. 10.4155/tde.10.1610.4155/tde.10.16 ↗
10. 10.1016/j.jconrel.2012.09.01710.1016/j.jconrel.2012.09.017 ↗
11. 10.1016/j.jconrel.2020.06.03910.1016/j.jconrel.2020.06.039 ↗
12. 10.1016/j.jconrel.2022.05.04510.1016/j.jconrel.2022.05.045 ↗
13. 10.1016/j.biomaterials.2007.12.04810.1016/j.biomaterials.2007.12.048 ↗
14. 10.1016/j.ijbiomac.2020.12.17710.1016/j.ijbiomac.2020.12.177 ↗
15. 10.1016/j.xphs.2023.04.00710.1016/j.xphs.2023.04.007 ↗
16. 10.1016/j.jconrel.2019.11.02310.1016/j.jconrel.2019.11.023 ↗
17. 10.1016/j.jconrel.2013.05.02610.1016/j.jconrel.2013.05.026 ↗
18. 10.1002/adhm.20170032610.1002/adhm.201700326 ↗
19. 10.3390/biomedicines810042710.3390/biomedicines8100427 ↗
20. 10.1016/j.msec.2016.03.09710.1016/j.msec.2016.03.097 ↗
21. 10.1038/s43586-022-00162-210.1038/s43586-022-00162-2 ↗
22. 10.1038/sj.jid.570015010.1038/sj.jid.5700150 ↗
23. 10.1038/micronano.2017.7310.1038/micronano.2017.73 ↗
24. 10.1016/j.actbio.2013.04.04510.1016/j.actbio.2013.04.045 ↗
25. 10.1038/s41591-019-0598-910.1038/s41591-019-0598-9 ↗
26. 10.1002/mabi.20220032310.1002/mabi.202200323 ↗
27. 10.1186/s40486-020-00113-010.1186/s40486-020-00113-0 ↗
28. 10.1007/s13346-021-01046-w10.1007/s13346-021-01046-w ↗
29. 10.1016/j.fbio.2018.06.00610.1016/j.fbio.2018.06.006 ↗
30. 10.1016/j.ijpharm.2014.05.04210.1016/j.ijpharm.2014.05.042 ↗
31. 10.1016/j.ijpharm.2017.02.01110.1016/j.ijpharm.2017.02.011 ↗
32. 10.3390/polym1318304310.3390/polym13183043 ↗
33. 10.1021/acs.molpharmaceut.1c0098810.1021/acs.molpharmaceut.1c00988 ↗
34. 10.1038/nm.218210.1038/nm.2182 ↗
35. 10.1007/s13346-016-0332-910.1007/s13346-016-0332-9 ↗
36. 10.3390/pharmaceutics1310160110.3390/pharmaceutics13101601 ↗
37. 10.1039/C7TB02082A10.1039/C7TB02082A ↗
38. 10.1016/j.ejpb.2022.11.01610.1016/j.ejpb.2022.11.016 ↗
39. 10.1021/acsami.2c1650210.1021/acsami.2c16502 ↗
40. 10.1371/journal.pone.016251810.1371/journal.pone.0162518 ↗
41. 10.1186/s40486-024-00204-210.1186/s40486-024-00204-2 ↗